Literature DB >> 2521843

Induction of tumor-cell lysis by bi-specific monoclonal antibodies recognizing renal-cell carcinoma and CD3 antigen.

J van Dijk1, S O Warnaar, J D van Eendenburg, M Thienpont, E Braakman, J H Boot, G J Fleuren, R L Bolhuis.   

Abstract

Bi-specific monoclonal antibodies (MAbs) were developed by somatic hybridization of 2 mouse hybridomas, one producing MAb against the G250 renal-cell carcinoma (RCC)-associated antigen and the other against the T-cell antigen CD3 (OKT3). The dual specificity of the hybrid MAb produced by these so-called quadromas was analyzed by immunohistochemistry on tissue sections and by cytotoxicity assays with relevant target and effector cells. The bi-specific MAb could induce TCR alpha beta/CD3+ and TCR gamma delta/CD3+ cloned lymphocytes to kill RCC cells. A noteworthy finding was that the TCR alpha beta and gamma delta lymphocyte clones showed different triggering abilities. The specificity of target-cell lysis by the cytotoxic T cells (CTL) was dictated by the specificity of the G250 MAb. Control bi-specific MAb, recognizing a cell-surface structure not involved in T-cell activation, did not induce lysis. Several IgG subclass switch variants of the G250 hybridoma, i.e., IgG1, 2a, 2b and IgE, were used for somatic hybridization with the OKT3 hybridoma (IgG2a). Except for IgE, all IgG subclass combinations could equally induce cytolysis. Induction of cytolysis was inhibited only by excess OKT3 MAb. Comparison of 2 bi-specific MAb preparations of the same combination (IgG2a/1), produced by 2 quadromas derived from the same parental hybridomas after identical purification procedures, produced different amounts of bispecific MAb.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2521843     DOI: 10.1002/ijc.2910430230

Source DB:  PubMed          Journal:  Int J Cancer        ISSN: 0020-7136            Impact factor:   7.396


  9 in total

1.  Bispecific-monoclonal-antibody-directed lysis of ovarian carcinoma cells by activated human T lymphocytes.

Authors:  S A Möller; R A Reisfeld
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

Review 2.  Rationale for immunotherapy of renal cell carcinoma.

Authors:  R Heicappell; R Ackermann
Journal:  Urol Res       Date:  1990

Review 3.  Bispecific antibody: a tool for diagnosis and treatment of disease.

Authors:  S Songsivilai; P J Lachmann
Journal:  Clin Exp Immunol       Date:  1990-03       Impact factor: 4.330

4.  Requirement of monocytes and T-helper cells during development of tumor cell cytotoxicity in targeted T cells.

Authors:  K A Smans; M F Hoylaerts; M E De Broe
Journal:  Cancer Immunol Immunother       Date:  1994-01       Impact factor: 6.968

Review 5.  T cell targeting in cancer therapy.

Authors:  R L Bolhuis; E Sturm; E Braakman
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

6.  Enhancement of the lytic activity of cloned human CD8 tumour-infiltrating lymphocytes by bispecific monoclonal antibodies.

Authors:  A Gorter; K M Krüse; P I Schrier; G J Fleuren; R J van de Griend
Journal:  Clin Exp Immunol       Date:  1992-01       Impact factor: 4.330

7.  Augmentation of interleukin-2-induced activation of human melanoma tumor-infiltrating lymphocytes by heteroconjugate antibody.

Authors:  P F Mansfield; M G Rosenblum; J L Murray; K Itoh
Journal:  Cancer Immunol Immunother       Date:  1991       Impact factor: 6.968

8.  The development and purification of a bispecific antibody for lymphokine-activated killer cell targeting against the rat colon carcinoma CC531.

Authors:  P J Kuppen; A M Eggermont; K M Smits; J D van Eendenburg; S P Lazeroms; C J van de Velde; G J Fleuren
Journal:  Cancer Immunol Immunother       Date:  1993-06       Impact factor: 6.968

9.  Generation of chimeric bispecific G250/anti-CD3 monoclonal antibody, a tool to combat renal cell carcinoma.

Authors:  R M Luiten; L R Coney; G J Fleuren; S O Warnaar; S V Litvinov
Journal:  Br J Cancer       Date:  1996-09       Impact factor: 7.640

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.